Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
November 22 2022 - 8:30AM
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,
Founder and Chief Scientific Officer, will present at the World
Vaccine & Immunotherapy Congress West Coast 2022 in San Diego
on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.
Dr. Tucker will provide an overview of Vaxart’s
Phase II trial for its oral pill COVID-19 vaccine candidate.
Vaxart recently announced positive top-line
Phase II clinical study results for its Wuhan S-only COVID-19 pill
vaccine candidate.
About VaxartVaxart is a
clinical-stage biotechnology company developing a range of oral
recombinant vaccines based on its proprietary delivery platform.
Vaxart vaccines are designed to be administered using tablets that
can be stored and shipped without refrigeration and eliminate the
risk of needle-stick injury. Vaxart believes that its proprietary
tablet vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart’s development programs currently include
tablet vaccines designed to protect against coronavirus, norovirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immune-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Contacts
Vaxart Media Relations: |
Investor Relations: |
Mark Herr |
Andrew Blazier |
Vaxart, Inc. |
FINN Partners |
mherr@vaxart.com |
IR@Vaxart.com |
(203) 517-8957 |
(646) 871-8486 |
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2023 to Sep 2024